Stereotactic ablative body radiotherapy for the treatment of spinal oligometastases by Chang, J. et al.
ACCEPTED VERSION 
 
J.H. Chang, S. Gandhidasan, R. Finnigan, D. Whalley, R. Nair, A. Herschtal, T. Eade, A. 
Kneebone, J. Ruben, M. Foote, S. Siva 
Stereotactic ablative body radiotherapy for the treatment of spinal oligometastases 
Clinical Oncology, 2017; 29(7):e119-e125 
 
 
© 2017 The Royal College of Radiologists. 
This manuscript version is made available under the CC-BY-NC-ND 4.0 license 
http://creativecommons.org/licenses/by-nc-nd/4.0/ 
Final publication at http://dx.doi.org/10.1016/j.clon.2017.02.004 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
      http://hdl.handle.net/2440/103566 
 
PERMISSIONS 
https://www.elsevier.com/about/our-business/policies/sharing 
Accepted Manuscript  
Authors can share their accepted manuscript: 
 […] 
After the embargo period  
 via non-commercial hosting platforms such as their institutional repository 
 via commercial sites with which Elsevier has an agreement 
In all cases accepted manuscripts should: 
 link to the formal publication via its DOI 
 bear a CC-BY-NC-ND license – this is easy to do, click here to find out how 
 if aggregated with other manuscripts, for example in a repository or other site, be shared in 
alignment with our hosting policy 
 not be added to or enhanced in any way to appear more like, or to substitute for, the 
published journal article 
Embargo 
0936-6555   Clinical Oncology  12 months   
 
2 July 2018 
Abstract: 
 
Aims: To report multicenter outcomes of patients with spinal oligometastases, 
treated with stereotactic ablative body radiotherapy (SABR). The primary 
objective was to estimate the widespread failure-free survival (WFFS) at 2 years 
– defined as freedom from metastases not amenable to local salvage therapy and 
death. 
 
Materials and methods: Patients with one to three metastases, treated with 
spinal SABR between January 2010 and July 2014 at four academic institutions 
were included in this retrospective review. The median dose/fractionation was 
24 Gy (range 16 – 52.5 Gy) in 2 fractions (range 1 – 3), and the median 
biologically effective dose (α/β = 10) was 52.5 Gy (range, 40 – 144.4 Gy). The 
WFFS, overall survival, freedom from local progression, and toxicity rates were 
described using Kaplan-Meier statistics. 
 
Results: 60 patients with 72 spinal metastases were analyzed. The median 
follow-up was 21 months. Patients had a median age of 66, ECOG performance 0-
1 in 97%, and metachronous oligometastases in 85%. The 1 and 2-year WFFS 
rates were, 67%, (95% confidence interval [CI], 55 – 80) and 59% (95% CI, 47 – 
75), respectively. The 1 and 2-year overall survival rates were 90% (95% CI, 83 – 
98) and 76% (95% CI, 64 – 91), respectively. The 1 and 2-year freedom from 
local progression were 92% (95% CI, 85 – 99) and 86% (95% CI, 75 – 99), 
respectively. There were 4 cases (6.7%) of vertebral compression fracture and 
no cases of radiation myelopathy. 
 Conclusion: Despite the use of relatively low biological doses respecting spinal 
cord constraints, SABR results in excellent 2-year local control rates with low 
morbidity. Through careful selection of patients with oligometastases, the 
majority of patients are alive and free from widespread metastases at 2 years. 
This cohort warrants further investigation in clinical trials of SABR.  
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Introduction 
 
The term oligometastases describes an intermediate state of cancer spread 
between localized disease and widespread metastasis [1]. When patients 
develop metastases from solid tumors, they are generally regarded as 
incurable [1]. However, long-term cures have been demonstrated in patients 
with limited metastatic disease in various different cancers [2-4]. An attractive 
consequence of the concept of oligometastases is that some patients with 
metastatic disease may still be curable using local therapies. 
 
Stereotactic ablative body radiotherapy (SABR) has been shown to be an 
effective, non-invasive alternative to surgery for treating oligometastases [1,5,6]. 
SABR refers to an external beam radiotherapy treatment that delivers a high 
biological dose of radiation with high geometric precision to an extra-cranial 
target, typically using one to five fractions, delivered using highly specialized 
planning and treatment delivery techniques [7]. There are multiple single cohort 
prospective studies and retrospective reviews of using SABR for the treatment of 
lung metastases, showing 2-year local control rates and overall survival rates of 
90 – 100% and 50 – 70%, respectively [5,6,8]. Other body sites (including lung, 
liver, adrenal and lymph nodes) have also been treated with SABR, with local 
control rates ranging from 67 – 95%, and 2-3-year survival rates in the range of 
30 – 64% [1,9]. 
 
Evidence for the spine being an appropriate target for SABR is emerging. 
Multiple prospective cohort and retrospective studies have been performed on 
SABR for spinal metastases, showing local control rates of approximately 80-
90%, with low rates of toxicity [10,11]. However, most are in the context of 
patients with significant metastatic burden and few studies have examined the 
use of spinal SABR specifically in the setting of oligometastases. Spinal SABR has 
theoretical shortcomings compared to other body sites. Due to concerns about 
causing radiation myelopathy [12] and vertebral compression fractures 
(VCF) [13], prescribed doses for spinal SABR are typically lower than those used 
in other body sites such as the lung and liver. Moreover, at the interface between 
the planning target volume (PTV) and the spinal cord, doses are typically 
compromised even further below the intended prescribed dose, in order to meet 
dose constraints for the spinal cord [12]. An example of a typical dose 
distribution achieved with spinal SABR, where the dose at the interface between 
the PTV and the spinal cord is lowered is shown in Fig. 1. This raises the 
possibility that treating spinal metastases with SABR may result in inferior 
outcomes to those reported in other sites in the body, where higher doses can be 
safely employed. 
 
The aim of this study is to evaluate the outcome of patients treated with spinal 
SABR in the oligometastatic setting. As patients with metastatic disease treated 
with local therapies are at significant risk of further distant relapse, we focus in 
particular on reporting patterns of failure in this cohort. 
 
Materials and Methods 
 
This was a multi-institutional retrospective review of patients with 
oligometastases undergoing SABR. Patients were recruited from Peter 
MacCallum Cancer Centre, Royal North Shore Hospital, Princess Alexandra 
Hospital, and William Buckland Radiotherapy Centre. This study was approved 
by the institutional ethics committees of all four hospitals. Patients were 
included in this study if they were treated with spinal SABR between 1 January 
2010 and 31 July 2014, and had oligometastases (defined as up to three 
metastases, all of which are treatable with extirpative or locally ablative 
treatment). Patients were excluded if they had more than 3 metastases at the 
time of SABR, had primary disease not treated with definitive intent, or had a 
hematological primary malignancy. Patient data was collected up until the study-
wide closeout date of 30 June 2015. 
 
Diagnostic MRI scans were fused to planning CT scans in all cases. Where 
possible, MRIs were performed on a flat tabletop to aid fusion. Clinical target 
volumes were defined according to consensus guidelines [14]. SABR was 
delivered in 1 to 3 fractions using either fixed gantry angle intensity-modulated 
radiotherapy (IMRT) or volumetric-modulated arc therapy (VMAT). 
Prescriptions were to covering isodoses, which varied between institutions, but 
were generally between 70% and 80%. SABR was prescribed to no more than 
three metastases in any treatment episode. The techniques for patient planning 
and treatment delivery varied between the four different institutions, and are 
described in Table 1. 
 
The primary objective was to characterize the widespread failure-free survival 
(WFFS). Widespread failure was defined as the development of metastatic 
disease not amenable to further locally ablative or extirpative therapy. WFFS 
was defined as the time from completion of SABR until widespread failure or 
death. We chose this as the primary endpoint to allow comparison to a previous 
study of SABR for oligometastases, which used a similar primary endpoint [15]. 
Secondary objectives included overall survival, freedom from systemic therapy 
initiation or change, progression-free survival, freedom from local progression, 
local progression-free survival, freedom from distant failure, distant failure-free 
survival, and freedom from widespread failure. Overall survival was censored 
either at the study-wide closeout date, or 90 days after the date of last clinical 
follow-up. All endpoints other than overall survival were censored either at the 
study-wide closeout date or the date of the last follow-up appointment. 
 
Three outcomes (WFFS, overall survival, and freedom from local progression) 
were further investigated for candidate explanatory prognostic factors on 
univariate and multivariate analyses. Potential prognostic factors included the 
BED10 (biologically effective dose, using the linear-quadratic model, assuming a 
tumor α/β of 10), number of metastases, primary histology (grouped into 
breast/prostate; sarcoma/melanoma/RCC, or other), Eastern Cooperative 
Oncology Group (ECOG) performance status, age, positron-emission tomography 
(PET) staging prior to SABR, and whether the treated lesion was a synchronous 
metastasis (defined as discovered within 4 months of the primary diagnosis) or 
metachronous (defined as discovered more than 4 months after the primary 
diagnosis). 
 Statistical analyses consisted of the production of Kaplan-Meier curves and 
univariate and multivariate Cox proportional hazards regression modeling, 
performed in the R statistical software package (R Development Core Team, 
2015) [16]. 
 
Results 
 
A total of 60 patients with 72 treated lesions were included in this study from 
the four participating institutions. The baseline characteristics are listed in Table 
2. The median follow-up was 21 months (range, 8 – 55). Fixed gantry angle IMRT 
was used for 53 patients and VMAT was used for 7 patients. The most common 
prescription doses for 1, 2 and 3 fractions were 20 Gy (n= 19), 24 Gy (n = 30), 
and 24 Gy (n = 11), respectively. The median BED10 was 53.5 Gy (range, 40 – 
144.4). Twenty six patients (43%) were staged with positron emission 
tomography (PET) whereas 34 patients (57%) were not (patient characteristics 
and specific radiotracers are listed in Table 2). 
 
The median WFFS was 25.4 months (95% confidence interval [CI], 20.4, upper 
limit undefined due to insufficient events). The 1 and 2-year WFFS were 67% 
(95% CI, 55 – 80%), and 59% (95% CI, 47 – 75%), respectively. The median 
freedom from systemic therapy initiation or change was 24.1 months (95% CI, 
15.1, upper limit undefined due to insufficient events). The 1 and 2-year freedom 
from systemic therapy initiation or change were 72% (95% CI, 61 – 85%) and 
51% (95% CI, 38 – 69%), respectively. 
 The 1-year, 2-year and median (where defined) outcomes for overall survival, 
freedom from systemic therapy initiation or change, progression-free survival, 
freedom from local progression, local progression-free survival, freedom from 
distant failure, distant failure-free survival, freedom from widespread failure, 
and WFFS are listed in Table 3. The Kaplan-Meier curves for WFFS, DFFS, overall 
survival and freedom from local progression are shown in Fig. 2. 
 
On univariate analysis of WFFS, the ECOG performance status (p < 0.001) and 
synchronous vs metachronous metastases (p = 0.026) were significantly 
prognostic. On multivariate analysis of WFFS, the ECOG performance status (p = 
0.001) and synchronous vs metachronous (p = 0.043) remained significantly 
prognostic. The hazard ratios (HR) for ECOG 0, 1 and 2 on multivariate analysis 
were 1, 4.11 (95% CI, 1.7 – 10.1), and 6.76 (95% CI, 1.4 – 33.3), respectively. The 
HR for metachronous and synchronous were 1 and 2.70 (95% CI 1.11 – 6.59), 
respectively. On univariate analysis of overall survival, the primary group (p = 
0.001) and ECOG performance status (p = 0.003) were significantly prognostic. 
On multivariate analysis, the primary group (p = 0.008) and ECOG performance 
status (p = 0.041) remained significant. The HR for breast / prostate, other, and 
sarcoma / melanoma / renal cell carcinoma were 1, 5.95 (95% CI, 1.2 – 29.9) and 
7.66 (95% CI, 1.8 – 32.3), respectively. On univariate analysis of freedom from 
local progression, only the ECOG performance status (p = 0.016) was 
significantly prognostic. The HR for ECOG 0, 1 and 2 were 1, 7.37 (95% CI, 0.8 – 
66.6) and 21.31 (95% CI, 1 – 348), respectively. 
 
Ten patients developed grade 1 acute toxicity (including fatigue, nausea, pain 
flare and esophagitis), and three patients experienced acute grade 2 toxicities 
(transient radiculitis and diarrhea). No patients experienced grade 3 or higher 
acute toxicities. Three patients developed grade 2 late toxicity (VCF causing 
pain) and one patient developed grade 3 late toxicity (VCF requiring a 
stabilization procedure). This corresponds to a crude rate of VCF of 6.7%. The 
median time until VCF was 15.4 months (range 1.1 to 24.6 months). No patients 
developed grade 4 or higher late toxicity. There were no cases of radiation 
myelopathy. 
 
Discussion 
 
In this study of 60 patients with oligometastases treated with spinal SABR, we 
found excellent 2-year freedom from local progression of 86%, with low toxicity 
rates including 6.7% VCF and no cases of radiation myelopathy. These findings 
are consistent with previous studies of SABR for non-spine sites in the setting of 
oligometastatic disease. Furthermore, overall survival in our cohort at 2-years 
was excellent at 76%, reflecting careful patient selection, limitation of definition 
of ‘oligometastases’ as 1-3 sites of disease, and utilization of PET screening. 
 
Our outcomes compare favorably with other extracranial oligometastatic cohorts 
of mixed histology. In our study we demonstrated a 2-year WFFS of 59% and a 2-
year overall survival of 76%. Milano et al. performed a prospective study of 121 
patients with five or fewer metastatic lesions, metastatic to one to three organ 
sites, treated with SABR. Multiple sites were treated including lung, liver, brain 
and bone [15]. The preferred treatment schedule was 50 Gy in 10 fractions. The 
2-, 4- and 6-year WFFS rates were 35%, 26%, and 21%, respectively. The 2-, 4-, 
and 6-year overall survival rates were 50%, 28%, and 20%, respectively. These 
outcomes are poorer than those found in our study, possibly because of our use 
of three metastatic lesions as a cut-off as compared with five metastatic lesions 
in this study. 
 
Salama et al. performed a prospective dose escalation study of 61 patients with 
five or fewer metastatic lesions treated with SABR [17]. Patients were treated in 
3 fractions, starting at 24 Gy, with subsequent patients treated at escalating 
doses up to 48 Gy. Multiple sites were treated including lung, liver, adrenals, 
pancreas, and bone (including vertebrae). The 2-year progression-free survival, 
overall survival, and freedom from local progression were 22.0%, 56.7%, and 
52.7%, respectively. These outcomes are poorer than that found in our study, 
again possibly reflecting the greater number of metastases treated in this cohort. 
 
Another important finding in our study was a median time until systemic 
therapy initiation or change of 24.1 months. This is longer than expected in a 
group with metastases. A prolonged interval before systemic therapy change or 
initiation is required may reduce side effects associated with systemic therapy 
initiation or change, which may have an impact on quality of life [18,19]. 
Decaestecker et al. performed a study of 50 patients with prostate primaries, 
with three or fewer metastatic lesions, all treated with SABR [19]. Multiple sites 
were treated including lymph nodes, liver, and bone (22% of which involved 
lesions in the axial skeleton). Patients were treated with either 50 Gy in 10 
fractions or 30 Gy in 3 fractions. Similar to our result for systemic therapy 
initiation or change, they reported a median androgen deprivation therapy free 
survival of 25 months. The 2-year progression-free survival and freedom from 
local progression were also similar to our study at 35% and 100%, respectively. 
 
It is important to note that none of these aforementioned oligometastases 
studies looked specifically at spinal metastases. One of the few such studies by 
Gill et al. performed was a retrospective review of 20 patients with single 
vertebral body oligometastases treated with SABR [20]. The most common 
primary histology was sarcoma, comprising 35% of treated patients. The 2-year 
overall survival and freedom from local progression were 57% and 73%, 
respectively, with inferior local control possibly related to relatively gentle 
median dose / fractionation schedule of 30Gy in 5 fractions as compared to our 
24Gy in 2 fractions, as previously described by Saghal et al. [21]  
 
It is interesting that outcomes achieved in our study were similar to those 
achieved with SABR for other body sites where much higher doses are usually 
required. A threshold dose of BED10 > 100 Gy is often quoted as being required to 
achieve optimal local control in lung and liver metastases [22,23], which is much 
higher than the doses employed in this cohort. This is an important 
consideration in this patient cohort because it is speculated that the close 
proximity of spinal SABR target volumes to the spinal cord may restrict the dose 
that can be safely delivered, and may therefore have inferior outcomes compared 
to sites where higher doses are typically delivered. Our comparable outcomes 
despite lower doses may be due to the intrinsically different natural histories of 
primary cancers that typically metastasize to the spine as the first site of 
oligometastases compared to other organs. Furthermore, there is also emerging 
evidence that different anatomical sites of metastasis (from the same primary 
histology) may have differing radiosensitivities [24]. 
 
The treatment of oligometastases is an area of intense international scientific 
activity, with multiple clinical trials currently underway. The Stereotactic 
Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic Tumors 
(SABR-COMET) trial is a randomized phase 2 trial of patients with controlled 
primary tumors, with maximum three metastases in any single organ 
system [25]. Patients are randomized to standard of care versus SABR to all sites 
of metastases. Their target accrual is 99 patients. The Stereotactic Ablative 
Radiotherapy for Oligometastatic Non-small Cell Lung Cancer (SARON) trial is a 
phase 3 randomized controlled trial of patients with non-small cell lung cancer 
with one to three metastases at any site in the body, randomized to either 
palliative chemotherapy alone, or to chemotherapy and radical radiotherapy 
(conventional radiotherapy and SABR) [26]. Their target accrual is 340 patients. 
These studies will help to define the role of local intervention with SABR in 
patients with oligometastatic disease. 
 
Our study has a number of limitations. The retrospective nature of this study 
limits the accuracy of data collection. Because there is no control arm, it is 
difficult to determine whether our favorable outcomes are due to patient 
selection. Our results should be carefully considered before extrapolation into 
clinical practice, as they are only generalizable when using similar patient 
selection criteria. In particular, a large proportion of our patients had prostate 
and breast primary histology (68%), and application of this data to a local 
practice with a different patient mix is cautioned against. Despite these 
limitations, these findings are still of significance as this is one of the few studies 
to look specifically into the subgroup of patients with spinal oligometastases. 
 
Conclusion 
 
SABR for spinal oligometastases results in excellent local control with low 
morbidity at 2-years. With careful patient selection, the majority of patients were 
alive and free from widespread metastases at 2 years. These results are 
consistent with studies of SABR for oligometastases at other body sites where 
higher radiotherapy doses are employed; indicating that SABR for spinal 
oligometastases is a promising strategy that should be further explored in 
prospective clinical trials. 
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Fig. 1. An example of a typical dose distribution achieved in a spine stereotactic 
ablative body radiotherapy plan prescribed to 24 Gy in 2 fractions with a spinal 
cord planning organ-at-risk limit of 17 Gy maximum point dose. The plan is 
demonstrated on a CT scan, zoomed in on the target T8 vertebra, shown in axial 
(a), sagittal (b), and coronal (c) planes. The planning target volume is shown in 
pink color wash, and the spinal cord PRV is shown in green color wash. The 
isodose lines are shown with dose legend on the right. 
 
  
Fig. 2. Kaplan-Meier curves for widespread failure-free survival (a), distant 
failure free survival (b), overall survival (c), and freedom from local progression 
(d) 
  
Table 1. Treatment protocols for the different institutions participating in this 
study 
 
 
PMCC RNSH PAH WBRC 
PTV margin 2 mm 3 mm 2-3 mm 1 mm 
CNT at level of 
spinal cord Spinal cord Spinal cord Spinal cord Thecal sac 
PRV margin 3 mm 2 mm 2-3 mm 0 mm 
CNT at level of 
cauda equina Thecal sac 
Nerve roots 
inside thecal 
sac Thecal sac Thecal sac 
PRV margin 0 mm 2 mm 2-3 mm 0 mm 
CNT PRV constraint 
for 1 fraction 
D0.035cc < 
12Gy 
V10Gy < 
0.35cc, V14Gy 
< 0.03cc 
Dmax <11-
12Gy 
D0.35cc < 
10Gy 
CNT PRV constraint 
for 2 fractions 
 
V10Gy <1.2cc, 
V14.5Gy 
<0.035cc 
Dmax <14-
16Gy 
 CNT PRV constraint 
for 3 fractions 
   
D0.35cc <18-
20Gy 
Treatment 
planning system Eclipse, iPlan Eclipse 
Eclipse, 
Pinnacle iPlan 
Immobilisation for BodyFIX BodyFIX BodyFIX none 
thoracic/lumbar 
spine 
On-board imaging 
CBCT, 
ExacTrac 
CBCT, 
ExacTrac CBCT 
CBCT, 
ExacTrac 
Timing of imaging 
CBCT initially, 
for 
verification, 
and mid-
treatment. 
ExacTrac 
every 1-2 
beam angles 
CBCT initially 
and for 
verification; 
ExacTrac with 
each couch 
rotation 
CBCT initially, 
for 
verification, 
and mid-
treatment (for 
long duration 
treatments) 
CBCT initially. 
ExacTrac for 
verification, 
and every 1-2 
beam angles 
Patient 
repositioning 
6 DOF couch 
with manual 
repositioning 
6 DOF robotic 
couch 
6 DOF robotic 
couch 
6 DOF robotic 
couch 
Linear accelerator 
Varian Trilogy 
/ Truebeam 
sTx 2.0 
Varian 
Truebeam sTx 
2.0 Elekta Axesse Novalis Classic 
MLC leaf thickness 5 mm, 2 mm 5 mm 4 mm 3 mm 
 
PMCC, Peter MacCallum Cancer Centre; RNSH, Royal North Shore Hospital; PAH, 
Princess Alexandra Hospital; WBRC, William Buckland Radiotherapy Centre; 
PTV, planning tumor volume; CNT, critical neural tissue; PRV, planning organ at 
risk volume; CBCT, cone beam CT; DOF, degrees of freedom; MLC, multileaf 
collimator 
  
Table 2. Baseline patient characteristics 
 
Variable 
 
Median (range) 
Age 
 
66 (23-84) 
Maximum dimension of 
treated lesion (cm) 
 
2.5 (0.1-6.3) 
GTV volume 
 
8.5 (0.1-193.2) 
CTV volume 
 
44.1 (5.9-273.1) 
Prescribed dose 
 
24 (16-52.5) 
Fractions 
 
2 (1-3) 
BED10 
 
53.5 (40-144.4) 
BED1.5 
 
230.2 (152-665) 
CTV median dose 
 
26.1 (15.6-50.3) 
   Variable Statistic n (%) 
Sex Male 49 (82%) 
 
Female 11 (18%) 
ECOG PS 0 35 (58%) 
 
1 23 (38%) 
 
2 2 (3%) 
Number of vertebrae 
treated 1 49 (82%) 
 
2 10 (17%) 
 
3 1 (2%) 
Location of lesions C1-C7 6 (10%) 
 
T1-T12 45 (75%) 
 
L1-L5 20 (33%) 
 
S1-S5 1 (2%) 
SINS score 0-6 45 (75%) 
 7-12 9 (15%) 
 
13-18 0 (0%) 
 
Surgical stabilisation 
prior to SABR 6 (10%) 
Timing of treated spinal 
metastasis Synchronous 9 (15%) 
 
Metachronous 51 (85%) 
Primary histology Prostate 35 (58%) 
 
Breast 6 (10%) 
 
Melanoma 6 (10%) 
 
Sarcoma 4 (7%) 
 
Kidney 1 (2%) 
 
Lung 4 (7%) 
 
Gastroesophageal 1 (2%) 
 
H&N 1(2%) 
 
Unknown primary 2 (3%) 
PET staging FDG PET 15 (25%) 
 
NaF PET 9 (15%) 
 
CHOL PET 2 (3%) 
 
No PET 34 (57%) 
Prostate cancer 
patients on androgen 
deprivation therapy at 
the time of SABR Yes 26 (43%) 
 
No 34 (57%) 
GTV, gross tumor volume; CTV, clinical tumor volume; BED10, biologically 
effective dose with α/β = 10; BED1.5, biologically effective dose with α/β = 1.5; 
ECOG PS, Eastern Cooperative Oncology Group Performance Status; SINS, spinal 
instability neoplastic score; PET, positron emission tomography; FDG, 18F-
fluorodeoxyglucose; NaF, 18F-sodium fluoride; CHOL, 11C-choline; SABR. 
stereotactic ablative body radiotherapy 
  
Table 3. Summary of outcomes 
 
Outcome 
1 yr. outcome (%) 
[95% CI] 
2 yr. outcome (%) 
[95% CI] 
Median outcome 
(months) [95% CI] 
Overall survival 90 [83, 98] 76 [64, 91] NA 
Freedom from systemic therapy 
initiation or change 
72 [61, 85] 51 [38, 69] 24.1 [15.1, NA] 
Progression free survival 59 [47, 73] 37 [25, 55] 18.1 [11.6, 25.4] 
Freedom from local progression 92 [85, 99] 86 [75, 99] NA 
Local progression free survival 85 [76, 94] 66 [52, 83] NA 
Freedom from any distant failure 63 [51, 77] 44 [32, 62] 19.0 [12.1, NA] 
Distant failure free survival 60 [49, 74] 43 [30, 60] 18.1 [11.9, NA] 
Freedom from widespread failure 69 [58, 83] 65 [53, 79] 28.3 [24.7, NA] 
Widespread failure free survival 67 [55, 80] 59 [47, 75] 25.4 [20.4, NA]  
 
CI = confidence interval 
 
